Table 5 The percentage of patients with a positive reaction (more than 0, at least 1%) to immune tests in the group of 30 patients with primary DCIS, in the same 30 patients with ipsilateral breast recurrence (columns 2, 3, respectively) and in 11 patients with primary DCIS without local recurrence (column 4)
Type of immune cells | Thirty patients with the initial DCIS before recurrence (%) | Thirty patients after detection of invasive recurrence (%) | Eleven patients without recurrence (%) |
|---|---|---|---|
CD20+ | 30/30 (100) | 30/30 (100) | 11/11 (100) |
CD163+ | 22/30 (73) | 26/30 (87) | 8/11 (73) |
CD138+ | 26/30 (87) | 30/30 (100) | 5/11 (45) |
CD4+ | 19/30 (63) | 23/30 (77) | 5/11 (45) |
CD8+ | 30/30 (100) | 27/30 (90) | 11/11 (100) |
FOXP3+ | 11/30 (37) | 20/30 (67) | 5/11 (45) |
TGF-beta | 9/30 (30) | 24/30 (80) | 2/11 (18) |